India's Stelis Biopharma To Make 200 Mn Doses Of Sputnik V Vaccine

Indian drugmaker Strides Pharma Science said on Friday its unit Stelis Biopharma has partnered with Russia's sovereign fund to make at least 200 million doses of the Sputnik V Covid-19 vaccine, bringing India's total production of the shot to over half a billion doses.

Stelis' pact with the Russian Direct Investment Fund (RDIF) follows similar deals struck by Indian pharmaceutical firms Gland Pharma and Hetero to make millions of doses of the vaccine, which has proven to be 91.6 per cent effective against Covid-19.

India has now become one of the biggest producers of Sputnik V outside of Russia. Other countries that are producing it include South Korea, Brazil and China.

Stelis and the RDIF intend to start supplies of the vaccine doses in the third quarter of this year, Strides Pharma said in a statement. There were no specific details on which countries the doses would be supplied.

Sputnik V, developed by Moscow's Gamaleya Institute, has been approved in 22 countries, with the RDIF signing supply deals with over 13 countries.

India, the world's biggest vaccine maker, has so far given emergency use approval to AstraZeneca Plc's shot and a homegrown vaccine made by Bharat Biotech.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor